Boston, MA -- (SBWIRE) -- 08/23/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: (XOMA Corp(NASDAQ:XOMA), Ann Inc(NYSE:ANN), Hercules Offshore, Inc.(NASDAQ:HERO), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
XOMA Corp(NASDAQ:XOMA) shares jumped 11.94% to $4.50. The company on August 20 announced the pricing of 7,596,685 shares of its common stock at a price to the public of $3.62 per share. In addition, XOMA anticipates its aggregate net proceeds from the offering will be approximately $25.5 million after deducting the underwriting discount and estimated offering expenses payable by XOMA. The offering is expected to close on or about August 23, 2013, subject to customary closing conditions.
How Should Investors Trade XOMA After The Recent Volatility? Get Free Report Here
Ann Inc(NYSE:ANN) shares increased 0.31% to $32.63. Janney Montgomery Scott upgraded Ann Inc. (NYSE: ANN) from Neutral to Buy with a fair value target of $38.00 (from $33.00), citing compelling valuation and limited downside on August 20.
Additionally, ANN INC., the parent Company of Ann Taylor and LOFT, and Vital Voices Global Partnership on August 1 announce that Anne Fulenwider, Editor-in-Chief of Marie Claire and Shelly Lazarus, an accomplished leader in the advertising world who is Chairman Emeritus and former CEO of Ogilvy & Mather, will serve as Advisory Council members for the ANNpower Vital Voices Initiative.
How Should Investors Trade ANN After The Recent Volatility? Get Free Report Here
Hercules Offshore, Inc.(NASDAQ:HERO) shares gained 5.43% to $6.99. The company, on July 31, said its second-quarter loss narrowed as the company reported stronger revenue amid dayrate improvement, though again faced significant one-time charges that dragged down results. The company reported a loss of $27.4 million, or 17 cents a share, compared with a year-ago loss of $55.1 million, or 35 cents a share. The company posted adjusted profit of a penny, compared with loss of 10 cents a year earlier. Revenue improved 37% to $211.5 million. Analysts recently predicted an adjusted profit of five cents a share on revenue of $225 million.
Is HERO A Good Buy After The Recent Price Movement? Find Out Here
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock gained 0.42% to $7.09. ARNA’s stock was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research note issued to investors on August 5. The firm currently has a $7.40 price objective on the stock.
Additionally, the company on Aug. 1 provided a corporate update and reported financial results for the second quarter ended June 30, 2013. Second quarter revenues totaled $68.9 million, including $1.3 million in net product sales and $65.5 million in milestone payments. Net income allocable to common stockholders was $40.1 million, or $0.18 per share.
Is ARNA A Strong Buy? Get Advantage Of Our Free Trend Analysis Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t be disappointed.
http://winstonsmallcap.com/and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)